Paul Tudor Jones II's position in Lilly(Eli) & is currently worth $59.7 Million. That's 0.74% of their equity portfolio (7th largest holding). The first Lilly(Eli) & trade was made in Q2 2013. Since then Paul Tudor Jones II bought shares 27 more times and sold shares on 24 occasions. The stake costed the investor $45.6 Million, netting the investor a gain of 31% so far.
… -Metabolic Medicine, Boehringer Ingelheim Pharmaceuticals , Inc. "Building … side effects of prescription drugs to the FDA. … 2023 Boehringer Ingelheim and...
EIN News Pharmaceuticals, about 1 month agoDriven by novel drugs from Biogen (BIIB) and Eli Lilly (LLY), the Alzheimer’s disease market will hit $13.7B in 2030, according to a new industry report. Rea...
Seeking Alpha, 11 months agoINDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said the DINAMO phase III clinical trial met its primary endpoint by showing a statistically significant...
Finanz Nachrichten, over 1 year ago